ReviewBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2016
Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies.
Review in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Advances in Nose-to-Brain Delivery Systems for Effective Alzheimer's Disease Management.Current Alzheimer research · 2026Review
- Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Demonstrating the Absence of Correlation Between Molecular Docking and in vitro Cytotoxicity in Anti-Breast Cancer Research: Root Causes and Practical Resolutions.Breast cancer (Dove Medical Press) · 2025Review
- Acute toxicity of trypsin inhibitor from tamarind seeds in embryo and adult zebrafish (Toxicology reports · 2024Article
- Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Development of an In Vitro Model for Inflammation Mediated Renal Toxicity Using 3D Renal Tubules and Co-Cultured Human Immune Cells.Tissue engineering and regenerative medicine · 2023Article
- Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer.Scientific reports · 2023Article
- Translating the determinant aspects on the study design in the dental implant field.Biomaterial investigations in dentistry · 2023Review
- High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer's disease using computational approaches.Journal, genetic engineering & biotechnology · 2021Article
- Review
- Improving target assessment in biomedical research: the GOT-IT recommendations.Nature reviews. Drug discovery · 2021Review
- Risk Management Framework for Nano-Biomaterials Used in Medical Devices and Advanced Therapy Medicinal Products.Materials (Basel, Switzerland) · 2020Article
- Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.Malaria journal · 2020Article
- Recent Advances in Monitoring Cell Behavior Using Cell-Based Impedance Spectroscopy.Micromachines · 2020Review
- Thermal Bioprinting Causes Ample Alterations of Expression of LUCAT1, IL6, CCL26, and NRN1L Genes and Massive Phosphorylation of Critical Oncogenic Drug Resistance Pathways in Breast Cancer Cells.Frontiers in bioengineering and biotechnology · 2020Article
- Flavopereirine-An Alkaloid Derived fromMolecules (Basel, Switzerland) · 2019Article
- Fucoidan Structure and Activity in Relation to Anti-Cancer Mechanisms.Marine drugs · 2019Review
- The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.Frontiers in pharmacology · 2019Review
- Article
- Pharmacokinetic parameters explain the therapeutic activity of antimicrobial agents in a silkworm infection model.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review presents a historical overview of drug discovery and the non-clinical stages of the drug development process, from initial target identification and validation, through in silico assays and high throughput screening (HTS), identification of leader molecules and their optimization, the selection of a candidate substance for clinical development, and the use of animal models during the early studies of proof-of-concept (or principle). This report also discusses the relevance of validated and predictive animal models selection, as well as the correct use of animal tests concerning the experimental design, execution and interpretation, which affect the reproducibility, quality and reliability of non-clinical studies necessary to translate to and support clinical studies. Collectively, improving these aspects will certainly contribute to the robustness of both scientific publications and the translation of new substances to clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.